Effect of different human papillomavirus serological and dnacriteria on vaccine efficacy estimates

American Journal of Epidemiology

Volumn 180, Issue 6, 2014, Pages 599-607

  Kuhs, Krystle A Lang ^a   Porras, Carolina ^b   Schiller, John T ^a   Rodriguez, Ana Cecilia ^b   Schiffman, Mark ^a   Gonzalez, Paula ^b,c   Wacholder, Sholom ^a   Ghosh, Arpita ^d   Li, Yan ^e   Lowy, Douglas R ^a   Kreimer, Aimée R ^a   Poncelet, Sylviane ^f   Schussler, John ^g   Quint, Wim ^h   Van Doorn, Leen Jan ^h   Sherman, Mark E ^a   Sidawy, Mary ⁱ   Herrero, Rolando ^b,c   Hildesheim, Allan ^a   Safaeian, Mahboobeh ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b PROYECTO EPIDEMIOLÓGICO GUANACASTE   (Costa Rica)

^c INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^d PUBLIC HEALTH FOUNDATION OF INDIA   (India)

^e UNIVERSITY OF MARYLAND   (United States)

^f GSK   (Belgium)

^g InformationManagement Services   (United States)

^h DDL DIAGNOSTIC LABORATORY   (Netherlands)

ⁱ GEORGETOWN UNIVERSITY   (United States)

Author keywords

Human papillomavirus; Methodological differences; Na ve population; Vaccine efficacy

Indexed keywords

VIRUS LIKE PARTICLE VACCINE; WART VIRUS VACCINE; VACCINE; VIRUS ANTIBODY; VIRUS DNA;

ASSESSMENT METHOD; BIOASSAY; CANCER; THRESHOLD; VACCINATION; VIRUS;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNOASSAY; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL; SEROLOGY; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS; CONTROLLED CLINICAL TRIAL; GENETICS; IMMUNOLOGY; METHODOLOGICAL DIFFERENCES; METHODOLOGY; NAÏVE POPULATION; PAPILLOMA VIRUS; PAPILLOMAVIRUS INFECTION; UTERINE CERVIX TUMOR; YOUNG ADULT;

COSTA RICA;

HUMAN PAPILLOMAVIRUS;

HUMAN PAPILLOMAVIRUS; METHODOLOGICAL DIFFERENCES; NAÏVE POPULATION; VACCINE EFFICACY;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; CERVICAL INTRAEPITHELIAL NEOPLASIA; DNA, VIRAL; DOUBLE-BLIND METHOD; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; SEROLOGIC TESTS; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84907487061     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwu168     Document Type: Article

References (17)

1. Schiller JT, Castellsagué X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine. 2012;30(suppl 5):F123-F138.
2. Hildesheim A, Herrero R, Wacholder S, et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: A randomized trial. JAMA. 2007;298(7):743-753.
3. Muñoz N, Kjaer SK, Sigurdsson K, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst. 2010;102(5):325-339.
4. Lehtinen M, Paavonen J, Wheeler CM, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA Trial. Lancet Oncol. 2012;13(1):89-99.
5. Safaeian M, Ghosh A, Porras C, et al. Direct comparison of HPV16 serological assays used to define HPV-naive women in HPV vaccine trials. Cancer Epidemiol Biomarkers Prev. 2012; 21(9):1547-1554.
6. Herrero R, Hildesheim A, Rodríguez AC, et al. Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica. Vaccine. 2008;26(37):4795-4808.
7. Herrero R, Wacholder S, Rodríguez AC, et al. Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: A community-based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discov. 2011;1(5):408-419.
8. Kleter B, van Doorn LJ, ter Schegget J, et al. Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomaviruses. Am J Pathol. 1998;153(6):1731-1739.
9. Kleter B, van Doorn LJ, Schrauwen L, et al. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol. 1999; 37(8):2508-2517.
10. Dessy FJ, Giannini SL, Bougelet CA, et al. Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine. Hum Vaccin. 2008;4(6):425-434.
11. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomised controlled trial. Lancet. 2004;364(9447): 1757-1765.
12. Malagón T, Drolet M, Boily MC, et al. Cross-protective efficacy of two human papillomavirus vaccines: A systematic review and meta-analysis. Lancet Infect Dis. 2012;12(10):781-789.
13. Einstein MH, Baron M, Levin MJ, et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a phase III randomized study of healthy women aged 18-45 years. Hum Vaccin. 2011;7(12): 1343-1358.
14. Draper E, Bissett SL, Howell-Jones R, et al. A randomized, observer-blinded immunogenicity trial of Cervarix® and Gardasil® human papillomavirus vaccines in 12-15 year old girls. PLoS One. 2013;8(5):e61825.
15. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356(19):1928-1943.
16. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356(19):1915-1927.
17. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: An interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007;369(9580): 2161-2170.